Background and Aims: We aimed to investigate the underlying mechanism of action of risankizumab, a monoclonal antibody targeting the IL-23 p19 subunit, previously reported to induce clinical and endoscopic remission in a randomised phase II study in patients with active Crohn's disease. Methods: Ileum and colon biopsies obtained at screening and Week 12 from a subgroup of patients [n = 106] in the risankizumab phase II study were analysed by transcriptome-wide RNA-Seq profiling. Univariate associations were assessed using linear modelling. Results: By Week 12, risankizumab significantly decreased [p < 0.005] the expression of 1880 and 765 genes in the colon [false-discovery rate = 0.02] and ileum [false-discovery rate = 0.05], respectively. These genes were associated with the IL-23/IL-17 axis, Th1 pathway, innate immunity, and tissue turnover. Colonic transcriptomic profiles following risankizumab treatment reflected the transcriptomic changes observed in patients achieving endoscopic response and remission at Week 12 and were significantly different from placebo [p < 0.005]. The colonic transcriptomic profile, significantly modulated by risankizumab at Week 12, was indicative of suppression of pathways associated with epithelial biology. Furthermore, pathways associated with Crohn's disease modulated by risankizumab treatment included second messenger-mediated signalling, immune response, lymphocyte and leucocyte activation, lymphocyte differentiation and cell-cell adhesion. Conclusions: Endoscopic remission and response observed with risankizumab in patients with active Crohn's disease was associated with significant transcriptomic changes in the colon, compared with placebo. Differentiated expression of genes associated with the IL-23/IL-17 axis was observed in the colon and ileum 12 weeks after risankizumab treatment.
Introduction
Crohn's disease [CD] is a chronic inflammatory bowel disease that is characterised by ulceration and transmural inflammation.
1 IL-23 is believed to be a key mediator in the pathogenesis of CD. [2] [3] [4] [5] The Th17/IL-23 pathway contains at least 22 proteins, and 10 of the encoding genes reside in loci that are associated with inflammatory bowel disease: IL23R, TYK2, RORC, IL21, IL12B, CCR6, JAK2, IFNG, SMAD3, and STAT3. 6 It has been hypothesised that the binding of IL-23 by the IL-23 receptor [IL-23R] results in activation of Janus kinase 2 [JAK2] and tyrosine kinase 2 [Tyk2] and subsequent phosphorylation of signal transducer and activator of transcription 1 [STAT1], STAT3, and STAT4, leading to the transcription of other pro-inflammatory cytokines. 7 This increased transcription of pro-inflammatory cytokines is thought to result in the differentiation of CD4+ T cells into pro-inflammatory Th17 cells and the generation of an inappropriate immune response to commensal bacteria or luminal antigens in the gut. 8 IL-23 promotes differentiation and also proliferation of Th17 cells through the IL-23R on Th17 cells, and patients with CD have elevated levels of IL-17A-and IL-22-producing T cells compared with healthy controls. 9 Further increased levels of peripheral Th17 cells have been observed in late but not early CD. 10 Selective inhibition of IL-23 with risankizumab, a monoclonal antibody targeting the IL-23 p19 subunit, 11 in randomised, double-blind, phase I [placebo-controlled] and randomised, doubleblind, phase II [active-controlled] clinical trials was associated with substantial and durable clinical improvement in patients with moderate-to-severe plaque psoriasis. 12, 13 More recently, risankizumab was more effective than placebo in inducing clinical remission, endoscopic response, and remission in patients with active CD. 14 Furthermore, risankizumab was shown to significantly reduce levels of biomarkers of disease activity in faeces and serum, such as faecal calprotectin and IL-22, and C-reactive protein in the serum, after 12 weeks of treatment.
14 Therefore, selective blockade of IL-23 via inhibition of p19 might be a viable therapeutic approach in CD.
The objective of the current biopsy sub-study was to gain an understanding of the mechanism of action of risankizumab, based on analyses of changes in the transcriptomic profile in the colon and ileum of patients with active CD in response to treatment. Association of these changes with endoscopic (CD Endoscopic Index of Severity [CDEIS] ) response and remission, as well as faecal calprotectin [FCP] levels was determined. We also gained insights into the effects of blockade of IL-23 on pathways related to inflammatory bowel disease identified from a published meta-analysis of multiple gene expression datasets. 15 
Materials and Methods

Study population and design
Tissue biopsy collection and processing
In the phase II study, biopsies were collected from 53 patients treated with risankizumab and 26 patients treated with placebo. Sites were instructed to collect 6-8 biopsy samples from the region in the colon and/or ileum with the most severe inflammation at baseline, and to obtain a second set of biopsies from the same location at Week 12. Multiple biopsy samples were collected in phosphate-buffered saline solution and pooled, with separate tubes for samples from ileum and samples from the colon, before the addition of RNAlater stabilisation reagent for analysis. RNA was purified after homogenisation using a Qiagen RNeasy Fibrous Tissue Mini Kit [Qiagen, Hilden, Germany] according manufacturer's instructions. Determination of RNA concentration and purity was performed by absorbance measurements using a NanoDrop spectrophotometer. For RNA sequencing, a polyA-based TruSeq V2 RNA sample preparation kit v2 [Illumina Inc., San Diego, CA] was used according to manufacturer's instructions on available ileum and colon biopsies from patients.
Transcriptome analysis of colon and ileum biopsies
Global transcriptome-wide sequencing of RNA from colon and ileum biopsy samples from the 79 patients described earlier was performed using the Illumina Hi-Seq 2000 [Illumina Inc., San Diego, CA, USA]. Sequenced reads were mapped to human genome version hg19 using STAR aligner. 16 Gene expression intensities and respective read counts were derived using cufflinks 17 based on Ensembl release 70. 18 An initial prefiltering step to remove transcripts with low expression was performed. A count of at least five was considered expressed. Based on the minimum library size of approximately 15 million, a cut-off of 0.3 counts per million was used and only transcripts with at least 10 in all location-treatment-visit groupings were selected. The samples were normalised using the trimmed mean of M-values [TMM] method.
The analyses to detect differential gene expression were performed at the univariate level. A repeated-measures linear regression model was used, with location of sample [ileum or colon], treatment [combined risankizumab doses or placebo], visit [baseline, Week 12] , and location-treatment-visit interaction as fixed effects and patient as a random effect. The appropriate contrasts were then calculated for the fold changes [FDs] between risankizumab and placebo in the ileum and the colon. The R-packages limma with voom transformation were used for analyses. To account for correlation between subjects, the duplicate correlation function was used with subjectlocation as a blocking factor; 19, 20 To compare genes expressed in the colon and modulated by risankizumab with genes dysregulated in patients with CD versus normal healthy controls, data provided by Granlund et al. 15 were used. Genes significantly deregulated in CD versus normal healthy controls [CD-N, corrected p ≤ 0.05, reported in the Supplementary 16 Read counts were obtained using subread's featureCounts, 24 based on miRBase v19 annotation. 25 Data were normalised using the TMM method described by Robinson and Oshlack, 25 and the limma package 19 was used to derive Log2FCs and corresponding FDR-adjusted p-values. Briefly, data were voom-transformed, 20, 26 correlations between baseline and Week 12 measurements per patient were estimated by the duplicateCorrelation function, a linear model was fitted using the lmFit-function and, finally, moderated t-statistics were computed. 27 For the NanoString data analysis, the background threshold for each lane was set to the mean count level of the negative controls plus two standard deviations. Next, the positive normalisation factor was calculated as the mean of all positive controls divided by the mean of positive controls for the respective lane. Finally, miRNAs count levels were normalised to the geometric mean of the top 100 expressed miRNAs. The average of the geometric means of the top 100 expressed miRNAs for all lanes divided by the geometric mean of the respective lane was used as the normalisation factor per lane.
Assessment of faecal calprotectin and faecal lactoferrin and correlation with CDEIS
Calprotectin was assessed in faecal samples collected at baseline and Week 12 using the Bühlmann ELISA test [Schönenbuch, Switzerland] . Lactoferrin was assessed in faecal samples collected at baseline and Week 12 using the IBD-SCAN® [TECHLAB, Blacksburg, VA]. Spearman's correlation coefficients were calculated for the correlations between the percent change from baseline in faecal calprotectin and faecal lactoferrin levels with change from baseline in CDEIS scores.
Ethics approval
The study protocol was approved by the institutional review board or ethics committee at each participating centre and conducted in accordance with applicable regulations and guidelines governing clinical study conduct, and with the ethical principles that have their origin in the Declaration of Helsinki. All patients who participated in the study provided written informed consent.
Results
Baseline patient characteristics
The baseline characteristics of the biopsy sub-population in the phase II study are described in Table 1 . The biopsy sub-population contained a higher percentage of women than men. There were no major differences between the treatment groups in disease duration or CDEIS scores, although the clinical pattern did vary somewhat. There was a higher percentage of patients classified as ileocolonic than as colon or ileum in the biopsy sub-population only. The majority of patients were TNF-antagonist experienced. Figure 1A ]. Of these reductions in expression, there were 491 genes with >1.5-fold decrease from baseline to Week 12 in the colon compared with 148 with >1.5-fold decrease from baseline to Week 12 in the ileum.
Significant changes in the expression of genes both unique and common to the colon and the ileum were associated with risankizumab treatment. Most genes that were decreased in the colon and ileum were associated with the pathogenesis of CD and the 
Pathway analyses of genes modulated by risankizumab in the colon versus the ileum
We assessed the effect of risankizumab on select biological states, processes, and signalling pathways, considering genes with absolute Figure 2A ]. Risankizumab treatment modulated genes associated with inflammatory response, several cytokine signalling pathways including IL-17, IL-6 JAK/STAT3, IFNγ, and IL-12 signalling, genes upregulated by KRAS activation, and TNFα signalling via NFκB in both the colon and the ileum [ Figure 2A ]. Apart from IL-12 signalling, in all of these gene sets or pathways more genes were differentially expressed in the colon compared with the ileum. Select genes associated with the Th17/IL-23 pathway modulated by risankizumab versus placebo in the colon are IL6  IL1B  SERPINE1  INHBA  CXCL6  CXCL1  OLR1  SOCS3  PTGS2  TLR2  CXCL9  CXCL11  IL23A  PLEK  SPP1  TNFAIP6  MMP3  MMP1  NOS2  CSF3  IFNG  IL17A  IL1A  CSF3R  G0S2  IL8  FPR1  SELE  MARCO  SLC2A3  FAP  CXCL2  FCN1  IL11  OSM  MEFV  AQP9  BCL6  REG1A  HSD11B1  NR4A3  CD274  CNTFR  FFAR2  ALDH1A2  IDO1  HMGCS2  MMP7  MMP13  BCL2A1  FCGR1A  STC1  S100A9  S100A12  PROK2  CXCL5  FOSL1  GAS1  SELL  SERPINA3  CLEC5A  LCN2  CXCL13  MMP10 15 CD, Crohn's disease; IFN, interferon; JAK, Janus kinase; NES, normalised enrichment score 33 ; STAT, signal transducer and activator of transcription; TNF, tumour necrosis factor; UV, ultraviolet.
shown in Supplementary Table S1, available as Supplementary data at ECCO-JCC online.
Other gene sets encoding IL-23 signalling, components of the complement system, angiogenesis, upregulated during transplant rejection [allograft rejection], and epithelial-mesenchymal transition were only significantly enriched by genes deregulated in the colon based on the chosen cut-offs.
Differential effects of risankizumab on the colon transcriptomic profile in patients with active CD has shown modulation of diseaserelevant gene ontogeny [GO] pathways, identified from a published meta-analysis of CD and UC Affymetrix datasets [ Figure 2B ]. 15 Risankizumab more strongly decreased expression of genes associated with pathways linked to second messenger-mediated signalling, lymphocyte differentiation, lymphocyte activation, leucocyte activation, immune response, and immune effector response compared with pathways associated with cell-cell adhesion, regulation of angiogenesis, anatomical structure, and development. . Risankizumabtreated patients who achieved endoscopic response or remission showed reduction in the expression of select genes in colon biopsies compared with patients who did not achieve endoscopic response or remission from baseline to Week 12 [ Figure 3 ]. Furthermore, there were select patients treated with risankizumab who were classified as not achieving endoscopic response, but appeared to show transcriptomic profiles similar to those with endoscopic response at Week 12. By contrast, patients receiving placebo showed increases in gene expression compared with those receiving risankizumab, reflecting the overall transcriptomic profile. In patients with the most severe endoscopic lesions [deep ulcerations] at baseline, a larger proportion of risankizumab-treated patients achieved endoscopic response at Week 12 compared with placebo, and these patients showed a transcriptomic pattern indicating reductions in the expression of key genes associated with active CD [ Figure 3 ]. Higher proportions of patients who had deep ulcerations at baseline in any segment of the colon achieved endoscopic response at Week 12 in the combined 200-mg and 600-mg risankizumab dose groups compared with patients with deep ulcerations in the ileum [ Table 2 ].
Transcriptomic profiles in risankizumab-treated patients versus placebo and association with endoscopic response and remission
Association of changes in faecal biomarkers with transcriptomic profiles
Significant reductions [baseline to Week 12] Figure 4A and B]. A correlation was observed between the expression of calprotectin at the protein level in faeces and the reduction in the expression of S-100A8 transcript in colon biopsies in patients treated with 600 mg risankizumab [r = 0.525, p = 0.0238] and associated changes in the transcriptomic profile, as reflected in Figure 4C . Furthermore, mucosal transcriptions of S-100A8 and S-100A9 [calprotectin] were decreased in patients with reductions in protein levels of faecal biomarkers [calprotectin/lactoferrin].
Association of changes in tissue and faecal miRNAs
Small RNA sequencing of colon biopsies comparing baseline and Week 12 samples identified 18 significant differentially expressed miRNAs [FDR-adjusted p < 0.05] in patients treated with 600 mg risankizumab [ Figure 5A ]. Of these, 13 miRNAs were downregulated and five miRNAs were upregulated by risankizumab. Comparing matching colon and faecal samples from 14 patients, a strong correlation was observed for miR-223-3p. However, none of the identified miRNAs was significantly differentially expressed in both the colon and faeces in a standard differential expression analysis by limma and nSolver, respectively [data not shown]. Downregulated levels of miR-223-3p at Week 12 were observed only in risankizumab-treated patients [ Figure 5B and C]. This result was not associated with endoscopic response or remission. Changes in levels of miR-223-3p, however, correlated with changes in faecal calprotectin levels in the 600-mg risankizumab dose group [ Figure 5D ].
Discussion
To our knowledge, this is the first study to characterise the effects of a selective anti-IL-23 antibody on the transcriptomic profile in the colon and ileum of patients with endoscopically active CD [despite most patients having had previous treatment with a TNF antagonist], which was significantly altered following 12 weeks of therapy with risankizumab. In this biopsy sub-population from the phase II study, patients treated with risankizumab who achieved endoscopic response or remission showed a differentiated transcriptomic profile in colon tissue compared with patients who did not achieve endoscopic response or remission at Week 12. A small number of risankizumab-treated patients classified as endoscopic non-responders had a similar transcriptomic profile in the colon as patients classified as endoscopic responders, suggesting that molecular changes in the tissue may precede endoscopic changes. These results may also represent small differences in the CDEIS scores between patients classified as endoscopic responders versus non-responders.
Greater changes in the number of genes expressed were observed in the colon compared with the ileum. Accordingly, there were several gene sets and pathways that were more significantly enriched by differentially expressed genes for the colon compared with the ileum. A recent study dissecting molecular pathways in the tissue of patients with CD, compared with non-inflammatory bowel disease patients, has shown differences in pathways related to interferon and interleukin signalling. 28 This is supportive of the relevance of our results from the enrichment analysis showing that risankizumab modulated gene sets associated with inflammatory response, IL-17, IL-6 JAK/STAT3, IFNγ signalling, and key pathogenic processes that occur in CD more strongly in the colon than the ileum. Previous studies have shown that patients who are refractory to anti-TNF therapies maintain differentially expressed genes in the colon 29 and the ileum, 30 consistent with our results. A limitation of this study was that biopsies were not collected from uninvolved mucosa, and thus treatment effects in healthy mucosa could not be assessed. However, a comparison of the changes in the transcriptomic profile by risankizumab in our study, with the changes in the transcriptomic profile dysregulated in patients with CD versus normal healthy controls previously reported by Granlund et al., 15 showed an overlap in 1063 genes upregulated in patients with CD versus healthy subjects and downregulated upon treatment with risankizumab. This overlap suggests that the genes evaluated do represent genuine effects of risankizumab treatment.
It is clear from the meta-analysis by Granlund et al., 15 focused on gene regulation and processes that were stably correlated with CD and ulcerative colitis disease, that a dominance of Th1 and Th17 pathways is observed. There was consistency in the normalised enrichment score across the most highly ranked categories and studies, implying that similar disease processes occur in both CD and ulcerative colitis. The most prominent pathways were those related to inflammation, as it is associated with innate and adaptive immunity, cell proliferation, as it is related to epithelial cell regeneration in response to tissue damage, and angiogenesis. We were able to build on this analysis to better understand the changes in the transcriptomic profiles in the colon and ileum upon treatment with risankizumab. Overall, many identified pathways were modulated by risankizumab treatment including second messenger-mediated signalling, immune response, lymphocyte/leucocyte activation, lymphocyte differentiation, and cell-cell adhesion.
In the subset of patients with biopsies, a higher proportion of patients with deep ulcerations in the colon, compared with those with deep ulcerations in the ileum at baseline, achieved endoscopic response at Week 12 following risankizumab treatment. A similar transcriptomic profile in the colon was observed in patients with deep ulcerations at baseline and endoscopic response versus those without deep ulcerations. The changes observed in the transcriptomic profile in the colon following 12 weeks of risankizumab treatment were not only associated with endoscopic responses and remission scores, but also with changes in faecal calprotectin levels. Furthermore, risankizumab-treated individuals with reductions in levels of faecal protein biomarkers [calprotectin and lactoferrin] showed decreases in the expression of S-100A8/A9 [calprotectin] genes in the colon and ileum. Increased expression levels of S-100A8/A9 genes and associated proteins released from neutrophils and macrophages have generally been observed in colon and ileum tissues and faeces of patients with CD, and correlate with elevated levels of Th17-associated cytokines. 31 Treatment with risankizumab decreased expression of genes and proteins associated with the Th17 pathway, including IL-23, IL-26, and IL-17A, and these changes were associated with reductions in S-100A8/A9 in patients with CD.
Increased levels of miR-223-3p have been observed in the serum of patients with CD compared with healthy controls. 32 IL-23 can induce the expression of miR-223-3p in intestinal tissue in patients with CD, and the associated downregulation of Claudin-8 [mRNA target] can result in a disruption of the homeostasis of the intestinal barrier. 32 Here, we have also shown that 18 miRNAs were deregulated in the colon of patients treated with risankizumab versus placebo at Week 12. miR-223-3p was among the greatest downregulated miRNAs in the colon and in the faeces.
In this study, we were able to link changes in the expression of select genes in the colon tissue with changes in select miRNAs and changes in faecal protein biomarkers. Furthermore, these changes in tissue biomarkers correlated with endoscopic response/remission. Larger transcriptomic changes from baseline to Week 12 were observed in colon 
